Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Ist Teil von
The New England journal of medicine, 2009-06, Vol.360 (23), p.2397-2405
Ort / Verlag
Waltham, MA: Massachusetts Medical Society
Erscheinungsjahr
2009
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
The need for new therapies to treat multidrug-resistant (MDR) tuberculosis is great. The new compound TMC207, a diarylquinoline that inhibits mycobacterial ATP synthase, shows promising activity against MDR tuberculosis. In this study involving 47 patients, the administration of TMC207, as compared with placebo, resulted in a shorter time to sputum-culture conversion and a significant increase in the proportion of patients achieving culture conversion to negative.
The new compound TMC207, a diarylquinoline that inhibits mycobacterial ATP synthase, shows promising activity against MDR tuberculosis. In this study, the administration of TMC207 resulted in a shorter time to sputum-culture conversion and a significant increase in the proportion of patients achieving culture conversion to negative.
Tuberculosis is a leading cause of death from infectious disease, second only to human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS).
1
In 2006, there were 9.2 million new cases of tuberculosis and 1.7 million deaths, with the burden of the disease occurring predominantly in the developing world.
2
It is estimated that one third of the world's population is infected with latent
Mycobacterium tuberculosis,
providing an enormous reservoir for future disease.
3
Treatment of tuberculosis is protracted and burdensome.
4
Tuberculosis control is further complicated by the synergy between tuberculosis and HIV/AIDS and by the emergence of multidrug-resistant strains of
M. tuberculosis
. . . .